Department of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Laboratory of Cellular Immunity, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
BMJ Open. 2024 Sep 13;14(9):e081293. doi: 10.1136/bmjopen-2023-081293.
Acupuncture is widely used for metabolic-associated fatty liver disease (MAFLD) treatment; however, the clinical efficacy has not been confirmed due to the lack of high-level evidence-based clinical practice. The purpose of this study is to design a research protocol that will be used to determine the efficacy of acupuncture versus sham acupuncture (SHA) for MAFLD treatment.
This will be a multicentre, randomised and sham-controlled trial. Ninety-eight participants with MAFLD will be enrolled in this trial. Participants will be randomly assigned in a 1:1 ratio to receive acupuncture or SHA for 12 weeks. The primary outcome is the rate of patients with a 30% relative decline in liver fat after 12 weeks of treatment in MRI-proton density fat fraction (MRI-PDFF), which will be obtained by quantitative chemical shift imaging such as the multipoint Dixon method at 0, 12 and 24 weeks. Secondary outcomes include the changes in the relative liver fat content measured by MRI-PDFF, magnetic resonance elastography, liver function, lipid metabolism, homeostatic model assessment for insulin resistance (HOMA-IR) and serum high sensitivity C reactive protein, which will be obtained at 0, 6, 12 and 24 weeks. Body measurement indicators (body mass index, waist circumference, hip circumference and waist-to-hip ratio) will be obtained at 0, 3, 6, 9, 12 and 24 weeks. The alteration in the gut microbiota composition and its metabolism will be assessed by 16S ribosomal RNA sequencing and liquid chromatography-mass spectrometry at 0 and 12 weeks.
This study protocol has been approved by the ethics committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (2023-1347-114-01). The results of this study will be published in a peer-reviewed journal and presented at academic conferences.
ChiCTR2300075701.
针灸广泛用于治疗代谢相关脂肪性肝病(MAFLD);然而,由于缺乏高水平的循证临床实践,其临床疗效尚未得到证实。本研究旨在设计一个研究方案,用于确定针灸与假针灸(SHA)治疗 MAFLD 的疗效。
这将是一项多中心、随机、 sham 对照试验。将招募 98 名 MAFLD 患者参加这项试验。参与者将以 1:1 的比例随机分配接受针灸或 SHA 治疗 12 周。主要结局是在 12 周 MRI 质子密度脂肪分数(MRI-PDFF)定量化学位移成像(如多点 Dixon 法)获得的治疗 12 周后肝脂肪减少 30%的患者比例,以及 0、12 和 24 周时获得的 MRI-PDFF、磁共振弹性成像、肝功能、脂质代谢、稳态模型评估胰岛素抵抗(HOMA-IR)和血清高敏 C 反应蛋白的相对肝脂肪含量变化,这些将在 0、6、12 和 24 周时获得。身体测量指标(体重指数、腰围、臀围和腰臀比)将在 0、3、6、9、12 和 24 周时获得。16S 核糖体 RNA 测序和液相色谱-质谱法将在 0 和 12 周时评估肠道微生物群落组成及其代谢的变化。
本研究方案已获得上海中医药大学曙光医院伦理委员会的批准(2023-1347-114-01)。本研究的结果将发表在同行评议的期刊上,并在学术会议上展示。
ChiCTR2300075701。